- Home
- Slides
- Home
- Tools and Resources
- Research Summaries for Consumers, Clinicians, and Policymakers
- Search for Research Summaries, Reviews, and Reports
- Research Available for Comment
- Submit a Suggestion for Research
- Submit Scientific Information Packets
- Comparative Effectiveness Research Grant and ARRA Awards
- News and Announcements
- What Is Comparative Effectiveness Research
- Who Is Involved in the Effective Health Care Program
- What Is the Effective Health Care Program
Slides
Add Presentation to Slide Tray
Presentation:
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Slides: 1–12 of 46
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Outline of Material
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | antirheumatic | rheumatic
Health Impact of Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic
Characteristics of JIA
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic
Treatment of JIA (1 of 2)
Keywords: anti-rheumatic | antirheumatic | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile chronic arthritis | juvenile rheumatic arthritis | rheumatic | juvenile idiopathic arthritis
Treatment of JIA (2 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic
DMARDs for Treating JIA (1 of 2)
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
DMARDs for Treating JIA (2 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
DMARDs Included in the Comparative Effectiveness Review
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a | azathioprine | D-penicillamine | hydroxychloroquine | leflunomide | methotrexate | sulfasalazine | adalimumab | etanercept | infliximab | abatacept | anakinra | rituximab | tocilizumab | intravenous immunoglobulin | IVIG
Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review (CER) Development
Keywords: systematic review | comparative effectiveness review
Rating the Strength of Evidence From the CER
Keywords: estimate of effect | evidence classification | evidence rating | strength of evidence
Clinical Questions Addressed by the CER (1 of 2)
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
Your slide tray is being processed.